Genomic Health, Inc. (NASDAQ:GHDX) Director Bros. Advisors Lp Baker sold 204,300 shares of the business’s stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $79.33, for a total transaction of $16,207,119.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Friday, November 9th, Bros. Advisors Lp Baker sold 169,344 shares of Genomic Health stock. The shares were sold at an average price of $82.51, for a total transaction of $13,972,573.44.

Shares of NASDAQ:GHDX opened at $78.89 on Friday. Genomic Health, Inc. has a one year low of $26.54 and a one year high of $92.18. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 7,889.00 and a beta of 0.44.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The firm had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $94.27 million. During the same period in the previous year, the firm posted ($0.06) EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, sell-side analysts anticipate that Genomic Health, Inc. will post 1.06 earnings per share for the current fiscal year.

Several equities research analysts recently commented on GHDX shares. Zacks Investment Research cut shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 24th. Piper Jaffray Companies boosted their price objective on shares of Genomic Health from $34.00 to $50.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Friday, August 3rd. Canaccord Genuity boosted their price objective on shares of Genomic Health from $56.00 to $62.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Finally, Cowen reaffirmed a “hold” rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. Genomic Health presently has an average rating of “Hold” and a consensus price target of $48.33.

Large investors have recently modified their holdings of the business. Globeflex Capital L P bought a new stake in Genomic Health during the 2nd quarter worth about $116,000. Sun Life Financial INC bought a new stake in Genomic Health during the 2nd quarter worth about $122,000. SG Americas Securities LLC bought a new stake in Genomic Health during the 2nd quarter worth about $162,000. Pacer Advisors Inc. bought a new stake in Genomic Health during the 3rd quarter worth about $171,000. Finally, Trexquant Investment LP bought a new stake in Genomic Health during the 3rd quarter worth about $202,000. 90.84% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Genomic Health, Inc. (GHDX) Director Bros. Advisors Lp Baker Sells 204,300 Shares” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/11/16/genomic-health-inc-ghdx-director-bros-advisors-lp-baker-sells-204300-shares.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Further Reading: How to interpret a stock’s beta number

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.